Category: Sleep Treatments

Sleep Treatments

Case Study Highlights Efficacy of myTAP Oral Appliance With Mouth Shield

A new case report demonstrates that combining the myTAP chairside titratable oral appliance with a mouth shield to enforce nasal breathing can significantly improve outcomes for patients with moderate-to-severe obstructive sleep apnea. The study highlights an 86% reduction in the apnea-hypopnea index, suggesting that minimal mandibular advancement paired with nasal patency support offers a highly effective, patient-friendly treatment approach.

Sleep Treatments

The CPAP Mask Feature with Greatest Positive Impact

A recent survey reveals what sleep techs, RTs, and lab managers value most in positive airway pressure interfaces.

Sleep Treatments

Surprising Duration of Self-Maintained Positional Therapy Benefits Offers New OSA Strategy

Research presented at ATS 2026 reveals that positional therapy conditions patients to avoid back-sleeping, maintaining obstructive sleep apnea control for up to a year after device withdrawal.

CPAP & PAP Devices

How to Afford CPAP + GLP-1 Polytherapy

What can sleep physicians do when obstructive sleep apnea patients can't afford every recommended therapy?

Insomnia Devices

Nexalin Acquires Digital Health Platform Ahead of FDA Pivotal Trial for Insomnia Treatment

The acquisition of PONM gives Nexalin ownership of the AI-integrated software supporting its HALO Clarity program, preparing for a 160-participant trial for moderate-to-severe insomnia.

Therapy Devices

Nyxoah Initiates Search for US-Based CEO to Accelerate Genio Launch

The medical technology company is transitioning leadership to focus on its next phase of growth and commercial traction for its obstructive sleep apnea therapy in the US market.

Pharmaceuticals

Semaglutide Associated With Lower Incidence of OSA in Post Hoc Analysis

A post hoc analysis of the SELECT trial suggests that semaglutide 2.4 mg is associated with a significantly lower incidence of obstructive sleep apnea in adults with overweight or obesity and established cardiovascular disease. While these findings are promising, Novo Nordisk notes that semaglutide is not currently approved to treat obstructive sleep apnea and further research is required.

Surgeries & Procedures

Which Costs Less: GLP-1s or Bariatric Surgery?

A retrospective study explores how surgical and pharmacologic weight-loss strategies stack up in cost, effectiveness, and health outcomes.

Behavioral Sleep Medicine

New DARC-NESS Model Explains Why Nightmares Persist in Children

A mastery-based cognitive-behavioral model centers on "nightmare efficacy" to help clinicians create personalized treatment plans for youth.